Novartis Ag (NVS) Common Equity (2016 - 2025)
Historic Common Equity for Novartis Ag (NVS) over the last 17 years, with Q4 2025 value amounting to $46.5 billion.
- Novartis Ag's Common Equity rose 549.11% to $46.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $46.5 billion, marking a year-over-year increase of 549.11%. This contributed to the annual value of $46.5 billion for FY2025, which is 549.11% up from last year.
- Latest data reveals that Novartis Ag reported Common Equity of $46.5 billion as of Q4 2025, which was up 549.11% from $44.8 billion recorded in Q3 2025.
- Novartis Ag's Common Equity's 5-year high stood at $67.8 billion during Q4 2021, with a 5-year trough of $38.2 billion in Q3 2023.
- In the last 5 years, Novartis Ag's Common Equity had a median value of $48.7 billion in 2021 and averaged $50.2 billion.
- In the last 5 years, Novartis Ag's Common Equity skyrocketed by 2197.12% in 2022 and then crashed by 3719.83% in 2023.
- Over the past 5 years, Novartis Ag's Common Equity (Quarter) stood at $67.8 billion in 2021, then fell by 12.38% to $59.4 billion in 2022, then fell by 21.33% to $46.8 billion in 2023, then decreased by 5.61% to $44.1 billion in 2024, then rose by 5.49% to $46.5 billion in 2025.
- Its Common Equity was $46.5 billion in Q4 2025, compared to $44.8 billion in Q3 2025 and $42.1 billion in Q2 2025.